Literature DB >> 21875287

MiR-138 suppresses expression of hypoxia-inducible factor 1α (HIF-1α) in clear cell renal cell carcinoma 786-O cells.

Tao Song1, Xu Zhang, Chunyang Wang, Yiguang Wu, Wei Cai, Jiangping Gao, Baofa Hong.   

Abstract

OBJECTIVES: Hypoxia-inducible factor-1alpha (HIF-1a) is widely considered to be one of the key regulators in cancer cells. Here, we investigated a microRNA regulating expression of HIF-1a and explored its functions in clear cell renal cell carcinoma (ccRCC) cells. METHODS AND MATERIALS: Western blot and reporter assays were used to assess HIF-1a as a direct target of miR-138. The effects of miR-138 or si-HIF-1a on ccRCC 786-O cells were also estimated by apoptosis analysis and cell migration assay.
RESULTS: The data showed HIF-1a to be one target of miR-138. Futhermore, inhibition of the expression of HIF-1a with specific siRNA or miR-138 could increase apoptosis and reduce the migration of 786-O cells.
CONCLUSIONS: miR-138 could inhibit the expression of HIF-1a and regulate the apoptosis and migration of ccRCC cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21875287

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  32 in total

1.  Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs.

Authors:  Jharna Datta; Mozaffarul Islam; Samidha Dutta; Sounak Roy; Quintin Pan; Theodoros N Teknos
Journal:  Oral Oncol       Date:  2016-03-19       Impact factor: 5.337

Review 2.  Reciprocal regulations between miRNAs and HIF-1α in human cancers.

Authors:  Wanli Yang; Jiaojiao Ma; Wei Zhou; Bo Cao; Xin Zhou; Hongwei Zhang; Qingchuan Zhao; Liu Hong; Daiming Fan
Journal:  Cell Mol Life Sci       Date:  2018-10-13       Impact factor: 9.261

3.  The clinical significance and regulation mechanism of hypoxia-inducible factor-1 and miR-191 expression in pancreatic cancer.

Authors:  Zhenguo Song; He Ren; Song Gao; Xiao Zhao; Huan Zhang; Jihui Hao
Journal:  Tumour Biol       Date:  2014-08-14

Review 4.  Warburg meets non-coding RNAs: the emerging role of ncRNA in regulating the glucose metabolism of cancer cells.

Authors:  Chenxiao Yu; Jiao Xue; Wei Zhu; Yang Jiao; Shuyu Zhang; Jianping Cao
Journal:  Tumour Biol       Date:  2014-11-28

5.  Selective expression of tumor necrosis factor-related apoptosis-inducing ligand mediated by microRNA suppresses renal carcinoma growth.

Authors:  Zhuo Zhang; Haiyan Zhang; Hongyan Li; Xiaoliang Chen; Meihan Liu; Dayu Liu; Yuanyuan Zhao; Xiangbo Kong
Journal:  Mol Cell Biochem       Date:  2014-05-01       Impact factor: 3.396

6.  MicroRNA-138 attenuates epithelial-to-mesenchymal transition by targeting SOX4 in clear cell renal cell carcinoma.

Authors:  Feng Liu; Linfeng Wu; Anping Wang; Yajun Xu; Xiaodong Luo; Xing Liu; Yi Hua; Deying Zhang; Shengde Wu; Tao Lin; Dawei He; Guanghui Wei; Shanwen Chen
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

Review 7.  OxymiRs in cutaneous development, wound repair and regeneration.

Authors:  Chandan K Sen; Sashwati Roy
Journal:  Semin Cell Dev Biol       Date:  2012-10-10       Impact factor: 7.727

Review 8.  Role of microRNA-138 as a potential tumor suppressor in head and neck squamous cell carcinoma.

Authors:  Yi Jin; Dan Chen; Robert J Cabay; Anxun Wang; David L Crowe; Xiaofeng Zhou
Journal:  Int Rev Cell Mol Biol       Date:  2013       Impact factor: 6.813

9.  miR-514a-3p functions as a tumor suppressor in renal cell carcinoma.

Authors:  Lu Jin; Yifan Li; Zeng Zhang; Tao He; Jia Hu; Jiaju Liu; Mingwei Chen; Yaoting Gui; Shangqi Yang; Xiangming Mao; Yun Chen; Yongqing Lai
Journal:  Oncol Lett       Date:  2017-08-31       Impact factor: 2.967

10.  Long non-coding RNA Linc00152 is a positive prognostic factor for and demonstrates malignant biological behavior in clear cell renal cell carcinoma.

Authors:  Yong Wu; Cong Tan; Wei-Wei Weng; Yu Deng; Qiong-Yan Zhang; Xiao-Qun Yang; Hua-Lei Gan; Tao Wang; Pei-Pei Zhang; Mi-Die Xu; Yi-Qin Wang; Chao-Fu Wang
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.